Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosomal protein S27 (MRPS27)
- Target
- MRPS27
- Molecular classification
- Structural ribosomal protein, Mitochondrial ribosomal protein, RNA-binding protein, Other (not a receptor, enzyme, transporter, ion channel, or transcription factor)
01
Overview
Mitochondrial ribosomal protein S27 (MRPS27) is a nuclear-encoded protein that is a component of the small (28S) subunit of the mammalian mitochondrial ribosome. It plays a vital role in mitochondrial protein synthesis by binding mitochondrial 12S rRNA and tRNA(Glu) and stimulating translation of key mitochondrial mRNAs, especially those encoding electron transport chain subunits. MRPS27 is also involved in positive regulation of cell proliferation and has been connected to tumor cell growth, suggesting a possible role in cancer biology. Mutations and variations in MRPS27 or other mitoribosomal proteins may be implicated in mitochondrial diseases (e.g., Leigh disease) and other metabolic or neurodegenerative disorders due to their central role in mitochondrial function. There are no drugs known to interact directly with MRPS27, nor is it considered a direct therapeutic target.
- Other names
- Small ribosomal subunit protein mS27MRPS27KIAA0264MRP-S27S27mtmS2728S ribosomal protein S27, mitochondrialMitochondrial 28S ribosomal protein S27Mitochondrial small ribosomal subunit protein mS27
02
Mechanism of action
Not applicable (no known drugs target MRPS27 directly)
03
Biological functions
Mitochondrial protein synthesisRNA bindingPositive regulation of cell proliferationPositive regulation of tumor cell growth
04
Disease associations
Metabolic/mitochondrial disorders (e.g. Leigh disease, plethora of newborns)Possible indirect role in cancer through cell proliferation/tumor cell growthOther neurodegenerative diseases (due to the connection with mitochondrial dysfunction)
05
Safety considerations
None known specific to MRPS27; however, targeting mitochondrial ribosomal proteins in general could risk impairment of mitochondrial translation and consequent cellular bioenergetic failure, meaning therapy directed at MRPS27 would likely have significant toxicity concerns
06
Interacting drugs
None known (no drugs targeting MRPS27 directly)
07
Biomarkers
Levels or mutations in MRPS27 and other mitochondrial ribosomal proteins could potentially serve as biomarkers for mitochondrial disease or dysfunction, but MRPS27 itself is not established as a specific clinical biomarker
Beyond the preview
Go deeper on Mitochondrial ribosomal protein S27 (MRPS27).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitochondrial ribosomal protein S27 (MRPS27).